- Accueil
- Research
- Our research groups
- Immunotherapy and biomarkers for immuno-oncology
Immunotherapy and biomarkers for immuno-oncology
Team
Alessandra NOTO | PhD, Senior Scientist |
| Victor JOO | PhD, Senior Scientist |
| Federica MARTINA | PhD, Biostatistician |
Douglas DAOUDLARIAN | Data manager and scientific coordinator |
| Robin BARTOLINI | Post-doc |
Research Focus
Our laboratory’s primary interest lies in unraveling the molecular and cellular pathogenesis of immunotoxicities with a focus on the discovery of new biomarkers for cancer immunotherapy, novel therapeutic targets for refractory irAEs, and immuno-modulation strategies to improve current therapies and develop the next generation cancer immunotherapies. Among the most challenging questions in identifying novel biomarkers for cancer immunotherapy is the characterization of the different immunological and physiological factors modulating irAEs and responses to cancer immunotherapy. Work in the Obeid lab takes advantage of the latest technology and leverages multi-omic methods including CyTOF and single-cell profiling of immune cells and in collaboration with clinicians and scientists across the Lausanne biomedical network.
I believe that the main objective of work in my lab is to provide a deep dissection of the immune system to conceive the next generation of immunotherapies in order to make cancer immunotherapy safer and more effective.
Current projects Covers
Our lab has several highly integrated human immunology projects:
- Decoding the pathogenesis of immunotoxicities
- Identification of new biomarkers for cancer immunotherapies (immune checkpoints inhibitors and CAR-T cell therapies)
- Developing new generation of immune checkpoints inhibitors (ICIs)
- Developing new immuno-modulation strategies to prevent and optimize the treatment of immune-related adverse events induced by CAR-T cell therapy and ICIs
Selected Publications
Risk Factors of Left Ventricular Systolic Dysfunction in Immune Checkpoint Inhibitor-Myocarditis
Yen-Chou Chen, Charles Dolladille, Anjali Rao, Nicolas Palaskas, Anita Deswal, Lorenz Lehmann, Jennifer Cautela, Pierre-Yves Courand, Salim Hayek, Han Zhu, Richard Cheng, Joachim Alexandre, Lauren Baldassarre, Francois Roubille, Michal Laufer-Perl, Aarti Asnani, Stephane Ederhy, Yuichi Tamura, Sanjeev Francis, elizabeth gaughan, Douglas Johnson, Danette Flint, Peter Rainer, guillaume bailly, Steven Ewer, Mandar Aras, Dimitri Arangalage, Eve Cariou, Roberta Florido, Giovanni Peretto, Osnat Itzhaki Ben Zadok, Nausheen Akhter, Anna Narezkina, Joshua Levenson, Yan Liu, shanthini crusz, nahema issa, Nicolas Piriou, Darryl Leong, shahneen sandhu, Isik Turker, Pedro Moliner, michel obeid, Lucie Heinzerling, Wei-Ting Chang, andrew stewart, vishnu venkatesh, Zoe Du, Anirudh Yadavalli, Dohyeong Kim, Alvin Chandra, Kathleen Zhang, John Power, Javid Moslehi, Joe-Elie Salem, and Vlad Zaha.
JACC CardioOncology in press 2025.
Immune profiling identifies predictive biomarkers and highlights the potential efficacy of IL-6R blockade in checkpoint inhibitor–related myocarditis
Sarah Boughdad, Douglas Daoudlarian, Robin Bartolini, Sofiya Latifyan, Jacqueline Doms, Hasna Bouchaab, Karim Abdelhamid, Nabila Ferahta, Nuria Mederos, Victor Joo, Antonia Stamatiou, Lucrezia Mencarelli, Nicolas Etienne, Khalil Zaman, Matthieu Perreau, Craig Fenwick, Keyvan Shabafrouz, Giuseppe Pantaleo, Solange Peters, Michel Obeid
medRxiv
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
Petit PF, Daoudlarian D, Latifyan S, Bouchaab H, Mederos N, Doms J, Abdelhamid K, Ferahta N, Mencarelli L, Joo V, Bartolini R, Stravodimou A, Shabafrouz K, Pantaleo G, Peters S, Obeid M
Ann Oncol. 2025 Jan;36(1):43-53
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.
Daoudlarian D, Segot A, Latifyan S, Bartolini R, Joo V, Mederos N, Bouchaab H, Demicheli R, Abdelhamid K, Ferahta N, Doms J, Stalder G, Noto A, Mencarelli L, Mosimann V, Berthold D, Stravodimou A, Sartori C, Shabafrouz K, Thompson JA, Wang Y, Peters S, Pantaleo G, Obeid M
Ann Oncol. 2024 Dec 17
Association of CD7⁺CXCR3⁺ CAR T cells with long-term remission in R/R DLBCL
Robin Bartolini, Lionel Trueb, Douglas Daoudlarian, Victor Joo, Alessandra Noto, Raphaël Stadelman, Bernhard Gentner, Craig Fenwick, Matthieu Perreau, Georges Coukos, Giuseppe Pantaleo, Caroline Arber, Michel Obeid
medRxiv
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
Pierre-Florent Petit, Douglas Daoudlarian, Sofiya Latifyan, Hasna Bouchaab, Nuria Mederos, Jacqueline Doms, Karim Abdelhamid, Nabila Ferahta, Lucrezia Mencarelli, Victor Joo, Robin Bartolini, Athina Stravodimou, Keyvan Shabafrouz, Giuseppe Pantaleo, Solange Peters, Michel Obeid
medRxiv
Distinct immune signatures are a potent tool in the clinical management of cytokine-related syndrome during immune checkpoint therapy
Douglas Daoudlarian, Amandine Segot, Sofiya Latifyan, Robin Bartolini, Victor Joo, Nuria Mederos, Hasna Bouchaab, Rita Demicheli, Karim Abdelhamid, Nabila Ferahta, Jacqueline Doms, Grégoire Stalder, Alessandra Noto, Lucrezia Mencarelli, Valérie Mosimann, Dominik Berthold, Athina Stravodimou, Claudio Sartori, Keyvan Shabafrouz, John A Thompson, Yinghong Wang, Solange Peters, Giuseppe Pantaleo, Michel Obeid
medRxiv
Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy.
Michel Obeid, Douglas Daoudlarian, Amandine Segot, Sofiya Latifyan, Hasna Bouchaab, Nuria Mederos, Karim Abdelhamid, Nabila Ferahta, Athina Stravodimou, Keyvan Shabafrouz, Solange Peters, Giuseppe Pantaleo
ResearchGate
Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity.
Power JR, Dolladille C, Ozbay B, Procureur AM, Ederhy S, Palaskas NL, Lehmann LH, Cautela J, Courand PY, Hayek SS, Zhu H, Zaha VG, Cheng RK, Alexandre J, Roubille F, Baldassarre LA, Chen YC, Baik AH, Laufer-Perl M, Tamura Y, Asnani A, Francis S, Gaughan EM, Rainer PP, Bailly G, Flint D, Arangalage D, Cariou E, Florido R, Narezkina A, Liu Y, Sandhu S, Leong D, Issa N, Piriou N, Heinzerling L, Peretto G, Crusz SM, Akhter N, Levenson JE, Turker I, Eslami A, Fenioux C, Moliner P, Obeid M, Chan WT, Ewer SM, Kassaian SE, International ICI-Myocarditis Registry, Johnson DB, Nohria A, Zadok OIB, Moslehi JJ, Salem JE
medRxiv. 2024 Jun 3
High-dimensional longitudinal immune profiling uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the coupling of immune-related adverse events to immune checkpoint inhibitor response.
Michel Obeid, Victor Joo, Douglas Daoudlarian, Robin Bartolini, Hasna Bouchaab, Sofiya Latifyan, Nuria Mederos, Karim Abdelhamid, Valérie Mosimann, Nabila Ferahta, Keyvan Shabafrouz, Giuseppe Pantaleo, and Solange Peters
Journal of Clinical Oncology
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V, Abdelhamid K, Noto A, Latifyan S, Martina F, Daoudlarian D, De Micheli R, Pruijm M, Peters S, Hullin R, Gaide O, Pantaleo G, Obeid M
Nat Commun. 2024 Apr 30;15(1):3664
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A, Hottinger AF, Latifyan S, Boughdad S, Becce F, Prior JO, Kuntzer T, Brouland JP, Dunet V, Obeid M, Théaudin M
J Neurol. 2023 Dec 23
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J, International ICI-Myocarditis Registry, Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE
Nat Med. 2023 Dec;29(12):3100-3110
Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J, International ICI-Myocarditis Registry, Cheynier R, Charmete
Nat Med. 2023 Dec;29(12):3268
Novel targets for immune-checkpoint inhibition in cancer.
Borgeaud M, Sandoval J, Obeid M, Banna G, Michielin O, Addeo A, Friedlaender A
Cancer Treat Rev. 2023 Nov;120:102614
A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells.
Joo V, Petrovas C, de Leval L, Noto A, Obeid M, Fenwick C, Pantaleo G
Front Immunol. 2023;14:1213375
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, Stein F, Bretagne M, Ederhy S, Fenioux C, Hamwy O, Funck-Brentano E, Romano E, Pieroni L, Münster JP, Allenbach Y, Anquetil C, Leonard-Louis S, Palaskas NL, Hayek SS, Katus HA, Giannitsis E, Frey N, Kaya Z, Moslehi J, Prifti E, Salem JE
Circulation. 2023 Aug 8;148(6):473-486
Neoadjuvant Immunotherapy: A Promising New Standard of Care.
Boydell E, Sandoval JL, Michielin O, Obeid M, Addeo A, Friedlaender A
Int J Mol Sci. 2023 Jul 24;24(14)
Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer.
Liu C, Shatila M, Mathew A, Machado AP, Thomas A, Zhang HC, Thomas AS, Faleck D, Funchain P, Philpott J, Grivas P, Obeid M, Carbonnel F, Wang Y
J Cancer. 2023;14(10):1913-1919
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies.
Godinho R, Noto A, Fenwick C, Stravodimou A, Hugelshofer S, Peters S, Hullin R, Obeid M
J Immunother Cancer. 2023 Jun;11(6)
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet MA, Gatta R, Wicky A, Gerard CL, Dalla-Vale M, Tavazzi E, Michielin G, Delyon J, Ferahta N, Cesbron J, Lofek S, Huber A, Jankovic J, Demicheli R, Bouchaab H, Digklia A, Obeid M, Peters S, Eicher M, Pradervand S, Michielin O
Front Oncol. 2022;12:1043675
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.
Ann Oncol. 2022 Oct 18
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A, Vionnet J, Obeid M, Bouchaab H, Peters S, Latifyan S, Wicky A, Michielin O, Chtioui H, Moradpour D, Fasquelle F, Sempoux C, Fraga M
J Immunother Cancer. 2022 Oct;10(10)
Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial.
Stalder G, Suffiotti M, Segot A, Noto A, Pantaleo G, Spertini O, Obeid M
Haematologica. 2022 Sep 8
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M, Suffiotti M, Pellaton C, Bouchaab H, Cairoli A, Salvadé V, Stevenel C, Hottinger R, Pythoud C, Coutechier L, Molinari L, Trono D, Ribi C, Gottardo R, Fenwick C, Pascual M, Duchosal MA, Peters S, Pantaleo G
JAMA Oncol. 2022 May 1;8(5):e220446
<sup>68</sup>Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M
J Immunother Cancer. 2021 Oct;9(10)
Reactivation of IgA vasculitis after COVID-19 vaccination.
Obeid M, Fenwick C, Pantaleo G
Lancet Rheumatol. 2021 Sep;3(9):e617
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, Vaucher J, Sempoux C, Peters S, Obeid M
J Thorac Oncol. 2021 Feb;16(2):318-326
Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis.
Özdemir BC, Latifyan S, Perreau M, Fenwick C, Alberio L, Waeber G, Spertini F, de Leval L, Michielin O, Obeid M
Ann Oncol. 2020 Dec;31(12):1775-1778
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.
Doms J, Prior JO, Peters S, Obeid M
Ann Oncol. 2020 Sep;31(9):1273-1275
Personalized treatment of immune-related adverse events - balance is required.
Martins F, Obeid M
Nat Rev Clin Oncol. 2020 Aug;17(8):517
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M
J Immunother Cancer. 2020 Jun;8(1)
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
Haanen J, Ernstoff MS, Wang Y, Menzies AM, Puzanov I, Grivas P, Larkin J, Peters S, Thompson JA, Obeid M
Ann Oncol. 2020 Jun;31(6):724-744
COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
Addeo A, Obeid M, Friedlaender A
J Immunother Cancer. 2020 May;8(1)
A Diffuse Medullary Hypercaptation With No Bone Lesion.
Christin A, de Leval L, Obeid M
JAMA Oncol. 2020 Feb 1;6(2):291-292
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M
Lancet Oncol. 2019 Jan;20(1):e54-e64
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, Obeid M
J Immunother Cancer. 2018 Dec 27;6(1):156
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
Ghosn J, Vicino A, Michielin O, Coukos G, Kuntzer T, Obeid M
J Immunother Cancer. 2018 Oct 22;6(1):110
Ecto-calreticulin in immunogenic chemotherapy.
Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, Ullrich E, de Botton S, Zitvogel L, Kroemer G
Immunol Rev. 2007 Dec;220:22-34
Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis.
Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G
Cell Death Differ. 2007 Oct;14(10):1848-50
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, A
Nat Med. 2007 Sep;13(9):1050-9
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G
Nat Med. 2007 Jan;13(1):54-61
Service d'immunologie et allergie
BH10-527
Rue du Bugnon 46
1011 Lausanne
+41 21 314 0790
Service d'immunologie et allergie
BH10-527
Rue du Bugnon 46
1011 Lausanne
+41 21 314 0790